These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19028932)

  • 21. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome.
    Byrne TA; Morrissey TB; Nattakom TV; Ziegler TR; Wilmore DW
    JPEN J Parenter Enteral Nutr; 1995; 19(4):296-302. PubMed ID: 8523629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised controlled trial of colostrum to improve intestinal function in patients with short bowel syndrome.
    Lund P; Sangild PT; Aunsholt L; Hartmann B; Holst JJ; Mortensen J; Mortensen PB; Jeppesen PB
    Eur J Clin Nutr; 2012 Sep; 66(9):1059-65. PubMed ID: 22828734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid replacement therapy with cholylsarcosine for short-bowel syndrome.
    Heydorn S; Jeppesen PB; Mortensen PB
    Scand J Gastroenterol; 1999 Aug; 34(8):818-23. PubMed ID: 10499484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macronutrient absorption characteristics in humans with short bowel syndrome and jejunocolonic anastomosis: starch is the most important carbohydrate substrate, although pectin supplementation may modestly enhance short chain fatty acid production and fluid absorption.
    Atia A; Girard-Pipau F; Hébuterne X; Spies WG; Guardiola A; Ahn CW; Fryer J; Xue F; Rammohan M; Sumague M; Englyst K; Buchman AL
    JPEN J Parenter Enteral Nutr; 2011 Mar; 35(2):229-40. PubMed ID: 21378253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open trial of octreotide long-acting release in the management of short bowel syndrome.
    Nehra V; Camilleri M; Burton D; Oenning L; Kelly DG
    Am J Gastroenterol; 2001 May; 96(5):1494-8. PubMed ID: 11374688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nutrient intake from habitual oral diet in patients with severe short bowel syndrome living in the southeastern United States.
    Estívariz CF; Luo M; Umeakunne K; Bazargan N; Galloway JR; Leader LM; Ziegler TR
    Nutrition; 2008 Apr; 24(4):330-9. PubMed ID: 18328409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon.
    Kapral C; Wewalka F; Praxmarer V; Lenz K; Hofmann AF
    Z Gastroenterol; 2004 Jul; 42(7):583-9. PubMed ID: 15248106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bovine colostrum to children with short bowel syndrome: a randomized, double-blind, crossover pilot study.
    Aunsholt L; Jeppesen PB; Lund P; Sangild PT; Ifaoui IB; Qvist N; Husby S
    JPEN J Parenter Enteral Nutr; 2014 Jan; 38(1):99-106. PubMed ID: 23264167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of hormonal growth factors in the treatment of patients with short-bowel syndrome.
    Jeppesen PB
    Drugs; 2006; 66(5):581-9. PubMed ID: 16620138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome.
    Ellegård L; Bosaeus I; Nordgren S; Bengtsson BA
    Ann Surg; 1997 Jan; 225(1):88-96. PubMed ID: 8998124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
    Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
    Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers.
    Emmanuel AV; Kamm MA; Roy AJ; Antonelli K
    Gut; 1998 Apr; 42(4):511-6. PubMed ID: 9616313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
    Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
    Houghton LA; Foster JM; Whorwell PJ
    Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fat-induced ileal brake in the dog depends on peptide YY.
    Lin HC; Zhao XT; Wang L; Wong H
    Gastroenterology; 1996 May; 110(5):1491-5. PubMed ID: 8613054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study.
    Buchman AL; Fryer J; Wallin A; Ahn CW; Polensky S; Zaremba K
    JPEN J Parenter Enteral Nutr; 2006; 30(6):487-91. PubMed ID: 17047172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.
    Naimi RM; Madsen KB; Askov-Hansen C; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():47-53. PubMed ID: 23501043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free fatty acids have more potent effects on gastric emptying, gut hormones, and appetite than triacylglycerides.
    Little TJ; Russo A; Meyer JH; Horowitz M; Smyth DR; Bellon M; Wishart JM; Jones KL; Feinle-Bisset C
    Gastroenterology; 2007 Oct; 133(4):1124-31. PubMed ID: 17919488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Energy intake, gastrointestinal transit, and gut hormone release in response to oral triglycerides and fatty acids in men with and without severe obesity.
    Dirksen C; Graff J; Fuglsang S; Rehfeld JF; Holst JJ; Madsen JL
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G332-G337. PubMed ID: 30520691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.